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Background: The severity of asthma varies in patients in primary care. The aim of this
study was to identify factors related to asthma severity in a primary care setting.
Methods: In this cross-sectional asthma study a random sample of 1477 patients, aged
15–45 years, from 42 primary health care centres received two questionnaires: one disease
oriented and one quality of life oriented, MiniAQLQ. A classification of the asthma severity
similar to the GINA guidelines was made with the information obtained from the
questionnaire. The classification was based on current treatment, use of rescue
medication, night symptoms, emergency consultations and use of oral steroids for
treatment of exacerbations.
Results: Thirty-five per cent of the women and 24% of the men were classified as having
severe asthma. Women used more inhaled corticosteroids, more often took long acting
beta-2 agonists or a leukotrien antagonist in addition to corticosteroids, experienced more
frequent night awakenings and were more often smokers than men. In a multivariable
analysis, female sex increased the odds of having severe asthma by 60% as compared with
male sex, age by 3% per year, not having the asthma prescription filled owing to cost by
59%, daily smoking by 66% and pollen allergy by 85%.
Conclusions: Female sex, age, pollen and pet allergy, not having the asthma prescription
filled owing to cost, and daily smoking were all independently associated with asthma
severity.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3149944; fax: +46 156 53533.
mail.telia.com (B. Sta¨llberg).Introduction
Asthma is a common chronic disease in people of all ages.
The majority of adolescent and adult patients with asthma
in Sweden are treated in primary care.1 The Global Initiative
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Factors related to the level of asthma severity 2077for Asthma (GINA) is a set of internationally accepted
guidelines for treatment and management of asthma.2 The
Swedish recommendations are similar to GINA implying early
treatment with inhaled corticosteroid (ICS) and adding long
acting beta-2 agonist (LABA) to a low or medium dose of ICS
when the asthma is insufficiently controlled.3 Leukotriene
receptor antagonist (LTRA) is only recommended as add-on
treatment to ICS in the Swedish guidelines.
According to several international studies, adherence to
prescribed treatment is low.4 One reason in Sweden could be
the high cost of the asthma medication, in spite of the
reimbursement system. It is unknown whether this affects
severity.
Assessing the severity level in daily asthma care has been
suggested in various guidelines and has also been used as a
prognostic factor.5 The GINA guidelines propose four severity
levels in patients on asthma medication: intermittent, mild
persistent, moderate persistent and severe persistent
asthma. These levels are based on medication, symptoms,
exacerbations and lung function. This classification has been
used in other studies.6
There is an indication of a sex difference among asthma
patients with a female predominance of severe asthma.6
However, other factors influencing the severity level in
asthma patients in primary care have not been studied. The
aim of this study was to identify factors related to asthma
severity in a primary care setting.SABA a
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Sampling
In the first phase of this project, the organisation of asthma
care at primary health care centres (PHCC) in the Uppsala-
O¨rebro region, central Sweden, was investigated.7 Of all 238
PHCCs, 16% had a complete asthma clinic, 37% had an
incomplete asthma clinic and 47% had no asthma clinic as
defined by the Swedish Respiratory Group in Primary Care.
In the second phase, 28 PHCCs with catchment areas with
fewer than 3000 inhabitants (and generally no asthma clinic)
were excluded from the study, as were four PHCCs that did
not have computerised medical records using the Interna-
tional Classification of Diseases (ICD-10) for diagnosis
registration, and 13 PHCCs that declined to participate.
The remaining 193 PHCCs were stratified into groups
according to the completeness of their asthma clinics and
catchment area size. From these strata, a proportional
random sample of 42 PHCCs was drawn.
Each of the 42 PHCCs generated a list of all patients with
asthma diagnoses attending the PHCC during the past 18
months. From these lists, samples of patients in the age
range 15–45 years were drawn. From lists containing 40 or
fewer, all patients were sampled, and from longer lists a
random sample of 40 patients was drawn, generating a total
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B. Sta¨llberg et al.2078Data collection
Two questionnaires were mailed to the patients with two
reminders when necessary. In the first questionnaire,
returned by 1136 (77%) patients, information was sought
on demographics, asthma medication, symptoms, allergy,
emergency consultations, smoking habits, occupation, sick
leave and patients’ knowledge about asthma treatment.
Four questions concerned the use of beta-2 agonists as
rescue medication, night awakenings, emergency consulta-
tions and use of oral steroids, i.e. the attainment of
treatment goals. An abbreviated English version of the first
questionnaire has previously been published.8
A simplified version of the asthma severity classification
with four levels of severity, intermittent, mild, moderate
and severe asthma, proposed in the GINA guidelines2 was
constructed. This was based on questionnaire information on
current treatment, the use of rescue medication, night
symptoms, emergency consultations and use of oral ster-
oids. The definitions of the severity levels used in this study
are seen in Fig. 1. The main difference from the GINA
guidelines was the lack of lung function data.
The second questionnaire was the asthma-specific quality
of life questionnaire, MiniAQLQ, developed to measure the
functional impairments most troublesome to adults with
asthma.9 This questionnaire was returned by 1098 (74.3%)
patients. It has been validated in patients from 17 years or
older but has also been used in studies with younger
patients. Patients were asked to recall their experience
during the last 2 weeks and respond to each question
on a seven-point interval scale, ranging from severe
impairment ( ¼ 1) to no impairment ( ¼ 7). The questions
were grouped into the four domains: ‘activity limitations’ (4
items), ‘symptoms’ (5 items), ‘emotional function’ (3 items)
and ‘environmental stimuli’ (3 items). The mean score for
each of the four domains and the overall score was
calculated and weighted with regard to the sampling
proportion.
A telephone interview was performed with 104 non-
responders (27% of the non-responders) out of whom 70
(67%) agreed to be interviewed. In these interviews, an
abbreviated form of the disease-oriented questionnaire was
used. In addition, some variables such as age and sex were
known for 90% of the 104 non-responders.
The Research Ethics Committee at Uppsala University,
Sweden, approved the study.Figure 2 Proportion of women and men with severe asthma in
groups according to age, whether or not they failed to have the
asthma prescription filled owing to cost and reported allergy
adjusted for the influence of smoking.Statistics
Data were analysed with the SPSS (version 13.0) and SAS
(version 6.12) statistical programme packages. The overall
partial non-response proportion (missing data in returned
questionnaires) was o0.15% with a specific variable max-
imum of 2%. Summary statistics such as means, proportions
and measures of dispersion were computed using standard
parametric methods. Simple differences between groups in
continuous data were tested with Student’s t-test or analysis
of variance, and differences in proportions with the chi-
square test. Multiple logistic regression was used for
analyses of variables influencing asthma severity, which also
provided odds ratios and their 95% confidence limits (CL).Linear regression was used to compute adjusted mean scores
and logistic regression to construct the regression surface in
Fig. 2.
p-Values o0.05 were considered as indicating statistical
significance. The mean of the total score and the four
domains were calculated in the MiniAQLQ. A difference
between groups in the quality of life scores of 0.5 units or
more has been claimed to be clinically significant.10
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Table 1 Patient characteristics.
Women Men P
n % n %
N 682 60.1 453 39.9 o0.001
Time with asthma Ns
o1 year 43 6.4 35 7.8
1–5 years 199 29.7 117 26.2
45 years 429 63.9 294 65.9
Daily smokers (%) 133 19.7 43 9.6 o0.001y
Reported allergy to
Pets (%) 438 65.0 300 66.7 Ns
Pollen (%) 439 64.8 278 61.9 Ns
Occupation (%) o0.001y
Student 212 31.8 102 23.0
Working full time 197 29.6 290 65.3
Working part time 142 21.3 17 3.8
Unemployed 37 5.6 22 5.0
Other 78 11.7 13 2.9
Sick leave for asthma last 6 months 142 23.5 84 19.4 Ns
Rescue medication Ns
More than twice a weekz 325 48.5 212 48.0
Night awakenings due to asthma the last week o0.01y
Never 462 68.6 336 78.5
One night 94 14.0 46 10.7
More than one night 117 17.4 46 10.7
Emergency consultations the last 6 months o0.001y
Never 483 71.7 364 81.3
Once 105 15.6 60 13.4
Twice or more 86 12.8 24 5.4
Oral steroids the last 6 months o0.001y
Never 553 82.3 402 91.0
Once 69 10.3 21 4.8
Twice or more 50 7.4 19 4.3
Annual follow up 260 40.5 194 46.2 Ns
Not having the asthma prescription filled owing to cost 197 29.2 140 31.3 Ns
p-Values were calculated with Z-test.
yp-Values were calculated with chi-square test.
zEither short acting beta 2-agonist or long acting beta 2-agonist as rescue medication.
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Characteristics of the study population
Patient characteristics are presented in Table 1. Sixty per
cent were women. The total mean age was 30.3 (SD 9.2),
with no difference between women and men. Two-thirds of
the patients reported an asthma history of more than 5
years. Allergy to pets was reported by 66% and allergy to
pollen by 64% without any sex difference. No allergy at all
was reported by 20%. There were no sex differences in terms
of age, asthma history, reported allergies and annual follow
up. Smoking was more frequent in women, 20% versus 10%for men. One-third of the patients did not have the asthma
prescription filled owing to costs. This was most apparent
among the younger patients (data not shown). About one-
fifth of all patients, with no sex difference, had been on sick
leave due to asthma at any time during the last 6 months. Of
those who had add-on treatment to ICS, a majority used
LABA. Only 4% used LTRA as add-on therapy and only two
patients used LTRA as monotherapy.
Women had experienced more frequent night awakenings
owing to asthma symptoms during the previous week than
men. During the previous 6 months, 28% of the women and
19% of the men had had emergency consultations at the
hospital or in primary care. Oral courses of steroids due to
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frequently by women (odds ratio 1.84, CL 95% 1.23; 2.74)
adjusted for smoking, medication level and occupation.Severity classification
As shown in Table 2, 30% of all patients were classified as
having severe asthma according to the classification in
Fig. 1. Women had more often severe asthma than menTable 2 Asthma severity, asthma medication and percentage on
All patients
n %
Asthma severity
Intermittent asthma 176 15.9
Mild asthma 177 16.0
Moderate asthma 419 37.9
Severe asthma 334 30.2
Asthma medication
Only SABA as needed 285 25.6
ICS regularly or in periods 456 41.0
ICS regularly or in periods and LABA or
leukotrienantagonist, regularly or in periods
372 33.4
Reported sick leave for asthma last 6 monthsy
Intermittent asthma 6 3.9
Mild asthma 15 9.4
Moderate asthma 55 16.1
Severe asthma 120 45.8
Asthma severity according to classification in Fig. 1.
SABA: short-acting beta 2-agonist; LABA: long-acting beta 2-agonist;
p-Values for differences between women and men were calculat
ySick leave for asthma includes patients absent from work or stud
were included.
Table 3 Asthma severity with mean (95% CL) of the overall Min
MiniAQLQ score
Overall score Symptom score Act
Intermittent asthma
Women 6.35 (6.21; 6.48) 6.28 (6.13; 6.44) 6.60
Men 6.37 (6.22; 6.51) 6.17 (5.96; 6.39) 6.69
Mild asthma
Women 6.01 (5.85; 6.16) 6.00 (5.83; 6.18) 6.20
Men 6.02 (5.83; 6.22) 5.89 (5.68; 6.09) 6.23
Moderate asthma
Women 5.66 (5.55; 5.77) 5.44 (5.31; 5.57) 6.05
Men 5.75 (5.63; 5.87) 5.47 (5.32; 5.63) 6.09
Severe asthma
Women 4.62 (4.47; 4.78) 4.28 (4.11; 4.46) 4.97
Men 4.75 (4.53; 4.97) 4.50 (4.27; 4.74) 5.18(po0.05). Patients with severe asthma had more sick leave
or absence from school than patients with a milder disease
(po0.001), but there was no sex difference. Women used
more ICS regularly or in periods and more often LABA or
leukotrien antagonists in addition to ICS. The distribution of
the severity of asthma among the patients was not
dependent on whether or not the PHCC had an asthma
clinic. Self-monitoring with peak flow meter and increased
knowledge about asthma were more frequent in patients
with more severe asthma (data not shown). The severitysick leave once or more for asthma during the last 6 months.
Women Men p
n % n %
o0.05
95 14.2 81 18.5
95 14.2 82 18.7
246 36.9 173 39.4
231 34.6 103 23.5
o0.05
151 22.6 134 30.2
287 42.9 169 38.1
231 34.5 141 31.8
Ns
1 1.3 5 6.8
8 9.5 7 9.3
28 15.1 27 17.4
82 48.0 38 41.8
ICS: inhaled corticosteroids.
ed with chi-square.
ies. Only eligible patients, working full or part time or students,
iAQLQ score and the different domains for women and men.
ivity score Emotion score Environment score
(6.50; 6.71) 6.25 (6.01; 6.48) 6.21 (6.02; 6.41)
(6.56; 6.82) 6.36 (6.16; 6.56) 6.28 (6.09; 6.46)
(6.02; 6.38) 5.96 (5.75; 6.17) 5.80 (5.58; 6.03)
(5.99; 6.47) 5.95 (5.66; 6.23) 6.05 (5.82; 6.28)
(5.93; 6.18) 5.54 (5.38; 5.71) 5.63 (5.49; 5.78)
(5.94; 6.23) 5.67 (5.49; 5.85) 5.86 (5.71; 6.01)
(4.79; 5.15) 4.53 (4.34; 4.72) 4.83 (4.63; 5.03)
(4.92; 5.43) 4.48 (4.15; 4.80) 4.90 (4.66; 5.14)
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owing to incomplete questionnaire responses.
Quality of life
There was a clinically relevant difference in the overall
MiniAQLQ score between patients with severe asthma and
those with less severe asthma (Table 3). There was also a
statistically significant difference in the overall MiniAQLQ
score between all severity groups (po0.01).
Factors associated with asthma severity
Factors associated with asthma severity are presented in
Table 4. Age, female sex, reported pollen allergy, not having
the asthma prescription filled owing to the cost, and daily
smoking were all independently associated with increased
probability of reporting severe asthma. Age increased the
odds of having severe asthma by 3% per year, female sex by
60%, pet allergy by 7%, not having the asthma prescription
filled owing to cost by 59%, daily smoking by 66%, and pollen
allergy by 85%. The odds ratios were similar in ordinal
logistic regression analyses of any severity.
The effects on the proportion of patients with severe
asthma of various combinations of the factors sex, age,
pollen allergy, and not having the asthma prescription filledTable 4 Factors influencing asthma severity.
Severe asthma All four severity
levels
ny ORz (95% CL)y ORz (95% CL)y
Age – 1.03 (1.02; 1.05) 1.04 (1.02; 1.05)
Sex
Female 231/682 1.60 (1.20; 2.12) 1.49 (1.19; 1.86)
Male 103/453 1.0 1.0
Pollen allergy
Yes 246/717 1.85 (1.36; 2.51) 1.52 (1.20; 1.94)
No 87/409 1.0 1.0
Pet allergy
Yes 232/738 1.07 (0.79; 1.44) 1.35 (1.06; 1.72)
No 100/386 1.0 1.0
Not having the asthma prescription filled owing to cost last
year
Yes 123/337 1.59 (1.20; 2.12) 1.74 (1.36; 2.22)
No 210/785 1.0 1.0
Daily smoker
Yes 73/176 1.66 (1.17; 2.36) 1.45 (1.06; 1.98)
No 279/944 1.0 1.0
Ordinal logistic regression.
yNumber of patients with the characteristic and severe
asthma as compared with the total number of patients with
the characteristic.
zOR (odds ratio) adjusted for all other variables in the
table.
y95% confidence limits.owing to cost are presented in Fig. 2. The proportion with
severe asthma ranged from 10% among the youngest men
with no pollen allergy and who filled their asthma prescrip-
tion to 56% among the oldest women with pollen allergy who
had not filled their asthma prescription.
Effects of non-response
There was no difference between the responders and non-
responders regarding age, sex, duration of asthma, pollen
allergy, not filling the asthma prescription owing to cost and
use of rescue medication.
Discussion
This study in primary care in Sweden has demonstrated that
women, smokers and patients with pollen allergy have a
greater risk of having severe asthma than others. Severe
asthma was also more common among patients who had not
all their asthma prescription filled owing to the cost, and the
proportion of patients with severe asthma increased with
age. Patients with more severe asthma had lower quality of
life.
The classification of severity is slightly modified in our
study in comparison with the classification for patients on
asthma treatment used in GINA guidelines. Using our
classification, two-thirds of the patients had moderate or
severe asthma. In recent years, many patients have received
additional treatment with LABA or LTRAs to ICS and
consequently more patients, with both our classification
system and the GINA guidelines are classified at a higher
severity level. Furthermore, we do not know if patients,
despite very mild disease, use combinations with ICS and
LABA in spite of the fact that monotheraphy with ICS is
recommended in mild asthma in the Swedish guidelines. In
those cases, patients will be classified as having a more
severe asthma both in our study and in the original
classification in GINA guidelines. Another possible explana-
tion to our result is that most patients with asthma in
Sweden, including those with moderate and severe disease,
nowadays are managed in primary care.
The patients in the study were recruited from records
with an asthma diagnosis during the previous 18 months. As
many patients with intermittent and mild asthma seldom
seek health care this could also be an explanation for the
low proportion of these groups of patients.
The majority of the study population were women. In
epidemiological studies in Sweden, women have a higher
prevalence of asthma than men.11 Another reason for the
sex difference could be that women have more severe
asthma and therefore more frequently consult doctors. On
the other hand, other studies imply that women, irrespec-
tive of disease, consult doctors more often than men.12
However, among our patients there was no sex differences in
annual follow up for asthma, but the total number of
appointments at the clinic for asthma was not measured.
Smoking also influences the disease and the effects of the
asthma medication.13 In Sweden, smoking has declined in
recent decades, but about 16% of the population are still
daily smokers, with a predominance for women.14,15 The
proportion of smokers in this study was lower than in the
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the time, and the sex difference in smoking habits was
greater.14
Contrary to guideline recommendations, many patients
took ICS, and in some cases also LABA, only in periods and
not regularly. One explanation could be that many patients
with asthma underestimate their symptoms,16,17 and there-
fore discontinue their medication in periods. Another reason
for the low adherence could also be that a high proportion of
patients had not having the asthma prescription filled owing
to cost, which was most apparent among the younger
patients.
The classification of severity levels used in this paper was
based on the GINA guidelines, but modified according to the
information obtained from the postal survey. The GINA
guidelines include lung function in the severity grading but
as no clinical examination was performed in this study, this
information was not available. The majority of general
practitioners normally do not perform spirometry regularly
in asthma patients and therefore their severity grading, in
most cases, is based only on clinical data without lung
function test. In addition, clinical studies have demon-
strated a weak correlation between lung function and
symptoms.18 The results from this study would probably
not have been different even if lung function data had been
available but this should be confirmed in future studies.
One advantage of this study is the large study population
randomly sampled in primary care with no selection bias.
The response rate was also high. The non-response analysis
revealed no signs of selection bias.
One limitation of the study is that the results were
entirely based on patient questionnaires and did not include
clinical examinations and lung function tests. Another
limitation of the study is that the random sample of patients
was based on those who had a diagnose of asthma and had
been attending their GP during the last one-and-a-half
years. Patients with very mild disease might not have the
need to attend their PHCC that often and would therefore
be excluded from the study. The prevalence of intermittent
och mild asthma known in primary care has also in other
studies been considerably lower than in epidemiological
studies.19
There was a strong association between asthma severity
and MiniAQLQ both for the overall score and the domains.
This was especially apparent between patients with severe
asthma and patients with less severe disease. This implies
that severity classification also has an impact on the
patients’ quality of life. A total score of 6.0 or more has
been proposed as a level for good asthma control.20,21 In our
study, 12% of the patients with severe asthma had an overall
score of more than 6.0, implying that in some cases severe
asthma does not have a dramatic impact on the quality of
life.
In this study, as well as in some other studies,6,22 there
was a significant sex difference in severity with 35% of the
women having severe persistent asthma, as compared with
24% of the men. When adjusted for other risk factors there
was a 60% greater risk of women having severe asthma.
Women reported more symptoms, more frequent exacerba-
tions and also more courses of oral steroids. This indicates
that the sex difference in severity not only was dependent
on the level of medication but also on the extent ofsymptoms. The reason for this sex difference is not
explained even though factors like other allergic comorbid-
ities and hormonal factors have been suggested.23–26
Allergy to pets and pollen is common in patients with
asthma,27 and allergy sensitisation is associated with
increased frequency of emergency visits.28 In this study,
we could not demonstrate any difference in self-reported
allergy to pollen or pets between the sexes.
In conclusion, this study of primary care demonstrates
that sex is an important factor for the level of severity of
asthma, with an increasing risk of severe asthma for women.
Age, reported pollen allergy, not having the asthma
prescription filled owing to cost and smoking were also
factors associated with an increased probability of severe
asthma. These factors might be important to consider when
managing asthma patients in clinical practice. The lack of
objective lung function data in our study should, however,
be addressed in future studies to confirm our conclusions
about asthma severity.
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